Neoflux
VC Fund
Seoul, South Korea
Neoflux is a venture capital firm based in Seoul, South Korea.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Neoflux invests in
Stages Neoflux invests in
Countries Neoflux invests in
Round sizes
Round size
- Series A
- $1.7M–$8.4M
- Series B
- $3k–$10M
Investment Focus
Industry
- Apps 3 (30%)
- Software 3 (30%)
- Medical 2 (20%)
- Big Data 2 (20%)
- Health Care 2 (20%)
Stage
- Series B 6 (60%)
- Series A 4 (40%)
Country
- South Korea 9 (90%)
- United States 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
1st Biotherapeutics
|
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1STBIO currently has 24 employees with expertise in biochemistry, medicinal chemistry,pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients. | $14.3M / Series B / Jul 30, 2020 | |
Thingsflow
|
Thingsflow is a chatbot that engages in the development and operation of the character chatbot brand Hellobot. | $1.9M / Series A / Jul 21, 2020 | |
BeMyCar
|
BeMyCar offers car rental services. | Series B / Mar 25, 2020 | |
Novelty Nobility
|
Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role.In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF)and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development. | $8.4M / Series A / Feb 04, 2020 | |
Grip
|
Grip is a mobile application that offers to sell products, update stories, go online and chat communication to sellers. | $3M / Series A / Jul 30, 2019 | |
Medical IP
|
Medical IP provides medical institution services for imaging analysis and 3D medical printing. | $4.8M / Series B / May 03, 2019 | |
Bitnine Global Inc.
|
Bitnine Global Inc. is providing Graph Database Management System solution and data modeling services. Bitnine Global Inc. who is oriented to resrearch & development activities shows 3 future visionsFirst, Bitnine Global Inc. provides core technologies of data analysis for the knowledge-based society by providing the best technology andgraph data solutions.Second, Bitnine Global Inc. We are trying to develop more valuable and advanced technologies by sharing our technologies and knowledge. So Bitnine Global Inc. will lead many communities in graph data domains in order to share our technology by using open source software.Third, Bitnine Global Inc. provides a core competency of eco-friendly green industry by providing core technologies for implementing the high level energy management system and efficient energy data processing techniques by combining the graph database methodology and big data. | $2.2M / Series A / Mar 13, 2018 | |
Yanadoo
|
Yanadoo is a fast-growing English conversation training company. Yanadoo offers an English vocabulary app that is designed to help users learn new words in 10 minutes a day. | $12M / Series B / Feb 28, 2018 | |
White Life Science
|
White Life Science is a pharmaceutical drug development company for human health. | $3K / Series B / Sep 01, 2016 | |
NBT
|
NBT is a mobile application that provides a customized accumulation system and knowledge-based technology on users' preferences. | $10.4M / Series B / May 27, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Neoflux invest in?
Neoflux invests primarily in Apps, Software and Medical startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Neoflux's check size?
Neoflux typically joins rounds of $1.7M–$8.4M at Series A and $3k–$10M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Neoflux participates in.
When did Neoflux last invest?
The most recent investment recorded for Neoflux closed in Jul 2020. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
